BACKGROUND: The effectiveness of antiviral therapy in preventing disease progression in patients with chronic hepatitis B and advanced fibrosis or cirrhosis is unknown. METHODS: Patients with chronic hepatitis B who had histologically confirmed cirrhosis or advanced fibrosis were randomly assigned in a 2:1 ratio to receive lamivudine (100 mg per day) or placebo for a maximum of five years. Of 651 patients, 436 were assigned to receive lamivudine and 215 to receive placebo. The primary end point was time to disease progression, defined by hepatic decompensation, hepatocellular carcinoma, spontaneous bacterial peritonitis, bleeding gastroesophageal varices, or death related to liver disease. An independent data and safety monitoring board mon...
OBJECTIVES: The aim of this study was to compare the virological and biochemical relapse rates in As...
Background and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine trea...
The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-neg...
BACKGROUND: The effectiveness of antiviral therapy in preventing disease progression in patients wit...
Background: Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanc...
Background/Aims: HBV-related chronic liver disease patients often present with hepatic decompensatio...
Background & Aims: Data on the long-term safety of lamivudine are limited. The aim of this analysis ...
Aim: To understand the efficacy of lamivudine in the initial treatment of chronic hepatitis B and to...
Hepatitis B virus (HBV) infection is a major cause of both acute and chronic liver disease world-wid...
AIM: To determine whether long-term lamivudine treatment in asymptomatic patients can reduce the ris...
Chronic hepatitis B continues to be a global problem, with an estimated 240 million cases according ...
Chronic hepatitis B continues to be a global problem, with an estimated 240 million cases according ...
Lamivudine was introduced as an antiviral for chronic hepatitis B over a decade ago. Its role in the...
Daniel C Chao, Ke-Qin HuDivision of Gastroenterology and Hepatology, University of California, ...
Background: Lamivudine has been widely used in chronic hepatitis B patients with hepatic decompensat...
OBJECTIVES: The aim of this study was to compare the virological and biochemical relapse rates in As...
Background and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine trea...
The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-neg...
BACKGROUND: The effectiveness of antiviral therapy in preventing disease progression in patients wit...
Background: Long-term effects of lamivudine treatment on chronic hepatitis B patients without advanc...
Background/Aims: HBV-related chronic liver disease patients often present with hepatic decompensatio...
Background & Aims: Data on the long-term safety of lamivudine are limited. The aim of this analysis ...
Aim: To understand the efficacy of lamivudine in the initial treatment of chronic hepatitis B and to...
Hepatitis B virus (HBV) infection is a major cause of both acute and chronic liver disease world-wid...
AIM: To determine whether long-term lamivudine treatment in asymptomatic patients can reduce the ris...
Chronic hepatitis B continues to be a global problem, with an estimated 240 million cases according ...
Chronic hepatitis B continues to be a global problem, with an estimated 240 million cases according ...
Lamivudine was introduced as an antiviral for chronic hepatitis B over a decade ago. Its role in the...
Daniel C Chao, Ke-Qin HuDivision of Gastroenterology and Hepatology, University of California, ...
Background: Lamivudine has been widely used in chronic hepatitis B patients with hepatic decompensat...
OBJECTIVES: The aim of this study was to compare the virological and biochemical relapse rates in As...
Background and Aims: This study assessed the efficacy and safety of up to 4 years of lamivudine trea...
The effect of lamivudine treatment on the outcome of patients with hepatitis B e antigen (HBeAg)-neg...